An interventional study of Stereotactic radiation therapy intervention and Surgical intervention in Lung Cancer (NSCLC), sponsored by Aarhus University Hospital. Recruiting at 4 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Aarhus University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 124 studies in Lung Neoplasms with a site in Denmark — 35 open to participants now, 47 under way, 8 of them phase 3. Lung Neoplasms · Denmark.
Among the 124 studies in Lung Neoplasms with a site in Denmark, this one is the 46th largest by planned enrollment of the 94 interventional ones that give a count, is one of 10 that started in 2026, is one of 46 with no phase, reaches primary completion later than 41 of the 46 other live ones, and was the 114th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →35 of the 124 studies in Lung Neoplasms with a site in Denmark are open now. Recruiting first, the newest first:
Vejle Hospital · Sites in Denmark
Ages 50+
Vejle Hospital · Sites in Denmark
Ages 50+
Ditte Krag-Hansen · Sites in Denmark
Ages 18+
Zealand University Hospital · Sites in Denmark
Ages 18+
Bristol-Myers Squibb · Sites in Denmark, United States, Argentina and 31 more countries
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
124 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 22 · Phase 3 16 · Phase 4 5
First in 1998; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 182 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 158 across the 94 interventional studies, 105 across the 30 observational. Of the 60 that completed or were terminated, 12 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 124 have an industry lead sponsor. The 10 most frequent:
Aarhus University Hospital is the lead sponsor of 298 studies on the registry; 80 are open to participants now.
Aarhus University Hospital has 5 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
12 of the studies in Lung Neoplasms with a site in Denmark that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT06537804Odense University HospitalProject Lung Cancer Screening in Southern Denmark | 2026-12-31 |
| NCT05053997Zealand University HospitalNavigate - Improving Survival and Quality of Life in Vulnerable Lung Cancer Patients | 2026-12-31 |
| NCT04699188Novartis PharmaceuticalsStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | 2027-01-25 |
Add all 12 to your calendar (.ics) → With an account.
Among the 124 studies in Lung Neoplasms with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In low-risk patients with stage I non-small cell lung cancer (NSCLC) surgical treatment with an anatomical resection is currently the standard of care.
For medically inoperable patients with stage I NSCLC, radiation therapy is currently the standard treatment. The latest generation of radiation therapy modalities is Stereotactic Body Radiation Therapy (SBRT).
In high-risk patients, minimal invasive surgery in terms of sublobar resection (wedge resection) with lymph node sampling is currently the recommended treatment approach for these patients, even though the evidence is limited. Additionally, SBRT is an alternative treatment option but the use in these patients is also based on weak evidence. So, it is highly warranted to compare these two treatment options in this group of patients in a randomized, controlled trial where selection bias can be eliminated. It is the specific aim of this study to provide such a trial allowing an evidence-based approach when deciding between surgery and SBRT as treatment for NSCLC in high-risk patients.
The STRADOS study (STereotactic RADiotherapy Or Surgery) is an open randomized, controlled national multicenter study in which high-risk patients with stage I non-small-cell lung cancer (NSCLC) are randomized to receive either surgical treatment with minimal invasive wedge resection with lymph node sampling, or SBRT.
The overall purpose of the study is to investigate the disease-free survival (DFS) after surgical treatment when compared to SBRT. The primary endpoint is DFS after 3 years. Secondary endpoint is quality of life after 1, 3, 6, 12 and 36 months. Tertiary endpoints are overall survival (OS) after 3 and 5 years; DFS after 5 years; re-admission adverse events and complications after 1, 3, 6, 12 and 36 months; health-care related costs within 12 and 36 months; PRO data - other than quality of life (QoL) (health condition, symptoms and functional level) after 1, 3, 6, 12 and 36 months and lung function test after 12 month.
BACKGROUND:
Lung cancer is the most frequently diagnosed cancer type worldwide with approximately 2.5 million new cases and 1.8 million deaths annually, making it a leading cause of cancer-related mortality. The incidence of early-stage lung cancer is increasing likely due factors such as incidental findings, screening, increased awareness and the introduction of cancer packages.
In low-risk patients with stage I non-small cell lung cancer (NSCLC) surgical treatment with an anatomical resection is currently the standard of care.
For medically inoperable patients with stage I NSCLC, radiation therapy is currently the standard treatment. The latest generation of radiation therapy modalities is Stereotactic Body Radiation Therapy (SBRT).
In high-risk patients' minimal invasive surgery with sublobar resection known as surgical wedge resection (SWR) with lymph node sampling is currently the recommended treatment approach for these patients but based on weak evidence.
EXISTING KNOWLEDGE:
SBRT has been reported to achieve 3-year overall survival (OS) rates ranging from 35 % - 65 %. There are several different possible reasons for the variability in outcome is multifactorial e.g., inclusion criteria's, co-morbidity and risk factors of patients.
Existing non-randomized trials comparing SBRT to SWR indicate that SWR may confer a survival advantage in terms of higher OS and DFS.
SWR has a lower risk of local recurrence, locoregional recurrence and regional recurrence and no lymph staging is performed in SBRT. The latter may lead to potential understaging and hence impact the indication for adjuvant therapy. However, it is extremely difficult to draw any firm conclusions due to selections bias of the conducted trials. In most studies SBRT patients have more risk factors than SWR patients, and selection bias is evident despite using advanced statistical method in terms of e.g. propensity matching.
The published systematic reviews and meta-analysis concluded that based on the non-randomized studies the outcome after SWR is probably better than after SBRT, but they all called for randomized, controlled trials. Two randomized, controlled trials have been initiated but both terminated before inclusion of the number of planned patients were reached due to slow recruiting. In the two trials, merely 58 patients were included, and analysis indicated better outcome in the SBRT group.
In terms of quality of life, Wisnivesky et al found in a non-randomized study from 2024 that SBRT provided a better quality of life immediately after treatment compared with SWR. However, both treatment groups reported similar quality of life at later time points, with a return to baseline quality of life suggesting that SWR and SBRT have a similar impact on the quality of life.
This has been confirmed by others, but never tested in a randomized setting, which is necessary in order to draw any firm conclusions.
ONGOING TRIALS:
In Clinicaltrials.gov three studies of interest are registered. In the POSTILV study (NCT01753414) (https://clinicaltrials.gov/study/NCT01753414?term=NCT01753414\&rank=1) it is planned to investigate anatomical resections (segmentectomy and lobectomy) with SBRT in low-risk patients. This is also the case in the VALOR study (NCT02984761) (https://clinicaltrials.gov/study/NCT02984761?term=NCT02984761\&rank=1) Accordingly, these two studies differ significantly from ours as these studies include low risk patients.
The STABLE-MATE study (NCT02468024) (https://clinicaltrials.gov/expert-search?term=NCT02468024) is actively recruiting. The study compares SWR to SBRT in high-risk patients with 3-year OS as primary outcome. The study is a multi-center study (48 sites) initiated in USA and predominantly recruiting patients from USA sites.
Informed consent in the STABLE-MATE study will be obtained after patients are made aware of the randomized assignment, which entails attrition bias, i.e. patients may prefer SBRT and will refuse participation when randomized to surgery. In addition, secondary endpoints are merely progression free survival and radiation toxicity.
The STRADOS trial will include e.g. quality of life and health care cost, and it is a national trial including all relevant sites in Denmark.
Despite the differences in the STABLE-MATE study and our study, the results are very likely to complement each other.
NOVELTY:
This project will address a critical gap in the treatment of lung cancer of how to best to treat this relatively large group of high-risk patients with lung cancer. It will have both national and international impact, especially because of the randomized design and being a national study including all relevant departments and hence including all applicable patients in Denmark
PURPOSE:
The overall purpose of this randomized, controlled trial is to investigate the 3-year DFS among high-risk patients with stage I NSCLC comparing SWR including lymph node sampling with SBRT (intervention).
ACRONYM:
STRADOS: STereotactic RADiotherapy Or Surgery
METHODS:
In the context of this study, a high-risk patient is defined as a patient that fulfills at minimum one of the main-risk criteria and/or two of the secondary criteria:
Main criteria:
Secondary criteria:
Patients:
Inclusion criteria:
Exclusion criteria:
Design:
Pre-randomization investigations:
Standard assessment according to the Danish national reference program for the assessment and treatment of lung cancer.
Sample size and power calculation:
The sample size calculation is based on the primary endpoint: 3-year DFS. The standard/control treatment is SWR, and the comparator/intervention is SBRT, and it set to be 70% and 50%, respectively.
The sample size is calculated with the 2-sided significance level of 0.05 and 80% statistical power, and hence 182 patients' needs to be included (91 patients in each of the two groups), and with an expected dropout of approximately 10%, a total of 200 patients will be included.
Data analyses:
Data extraction is done from RedCap database. Before data analysis a statistical analysis plan will be presented. Data analysis is performed using STATA 18 (StataCorp LLC, Texas, USA).
Endpoints for the individual group will be described with median and percentile, as we assume that data are not normally distributed.
We will use the ANOVA test to analyze repeated measurements (e.g. PROs) with treatment and time as systematic effects and patient as a random effect. The Χ2 test will be used when comparing the two treatments. All data are analyzed according to the intention to treat (ITT) principle, but a per protocol analysis will also be performed.
Data management:
All data are entered in a Case Report Form in RedCap (Research Electronic Data Capture - REDCap Consortium, Vanderbilt University Medical Center, Tennessee, USA). The Danish Data Inspectorate's guidelines are followed when handling, processing, and archiving collected data. All personally identifiable data are deleted at the end of the study.
All collected data are stored at the at Aarhus University. Data collection media are REDCap and electronic patient records.
Ethical considerations and inclusion of patients:
There is currently no evidence nor evidence-based consensus on which of the treatments investigated in this study is best (minimal invasive SWR or SBRT).
The individual patient will not benefit immediately from participating in this study, and the results of the study will only benefit future patients.
The procedure inclusion of patients and obtaining informed consent above ensures that the individual patient has the possibility to use or abstain from the usual 24 hours to consider study participation. From an ethical perspective the latter is important since some patients will wish to prioritize both study participation and at the same time not want a delay in time for referral though this is typically 24 hours. In the study population, a 24-hour delay in referral for definite treatment will not influence the outcome of the treatment or at a long term for the patient (e.g., mortality, and morbidity).
Risk:
The risks of surgical resection are predominantly bleeding, conversion to open surgery (thoracotomy), cardiac arrhythmias, postoperative air leakage from the lung, dyspnea, pain (both acute and chronic), and redo-surgery. The risks of SBRT are mainly pain, rash, rib fracture and radiation-induced pneumonitis. Overall, we believe that the knowledge gained from this study outweighs the disadvantages that patients might experience by participating.
Study approvals and registration:
The project is carried out in accordance with the Helsinki II Declaration and European regulations. The Scientific Ethics Committees for Denmark, the Data Protection Agency, is applied for permission to complete the program. Information concerning the patients is protected under the Personal Data Processing Act and the Health Act. The trial is registered at www.clinicaltrials.gov.
ORGANISATION:
A steering committee is responsible for the design, conduct, analysis and reporting the results of the trial. The multidisciplinary steering committee includes Thomas Decker Christensen MD, PhD (thoracic surgery) (PI), Christian B. Laursen, MD, PhD (respiratory medicine) (Co-PI), Peter Licht MD, PhD (thoracic surgery), Rene Horsleben Petersen MD, PhD (thoracic surgery), Tine Schytte MD, PhD (oncology) Weronika Maria Szejniuk MD, PhD (oncology) and Asger Roer Pedersen MSc, PhD (statistical supervisor). A total of approximately 33 Danish and international health care professionals with a multi-disciplinary background (e.g., oncologist, thoracic surgeons, respiratory physicians and radio physics) has read, commented and accepted the protocol and the initiation of the study.
International project collaborators and advisors:
Thoracic Surgery:
Oncology:
Respiratory Medicine:
Implementation:
This is a pragmatic, national, multicenter study conducted within a well-established national reference program for lung cancer diagnosis and treatment. Regardless of whether the results are positive or negative, they can be rapidly integrated into the national reference program, minimizing the time from clinical research to clinical implementation. At the end of the study a one-day seminary dedicated to ensuring an implementation strategy of study results into the national reference program is planned.
Clinical and national and international perspective:
This project will address a critical gap in the treatment of lung cancer of how to best to treat this relatively large group of patients with lung cancer. The results of the trial will impact evidence-based treatment both nationally and internationally.
Ultimately, the project aims to improve morbidity and reduce morbidity and improve quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A high-risk patient is a patient that fulfills at minimum one of the main-risk criteria and/or two of the secondary criteria:
Main criteria:
Secondary criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who are randomized to have surgery undergo a SWR via a minimal approach (VATS or RATS) during general anesthesia. Pre- and postoperative care and treatment is offered in accordance with local department guidelines. The surgery must be performed or supervised by a specialist in thoracic surgery. The operation is performed with the patient in lateral recumbent position. The surgeon decides the number of ports (1-4), and local analgesic is applied at the incision sites and/or as a nerve block. Additional pain management is registered and performed according to the local practice at the individual department. At the end of surgery, a chest tube is inserted in pleura through one of the ports, and the tube is connected to suction at levels decided by the treating surgeon. Patients in which minimal surgery is converted to thoracotomy are included in an intention-to-treat analysis.
Procedure: Surgical intervention
The SBRT planning technique is based on recommendations from the Advisory Committee on Radiation Oncology Practice (ACROP) guideline and the ICRU report 91: Prescribing, Recording and Reporting of Stereotactic Treatments with Small Photon Beams as implemented in the recommendations from the Radiotherapy Committee of Danish Oncology Lung Cancer Group. Planning should be guided by respiratory guided CT scans
Radiation: Stereotactic radiation therapy intervention
The SBRT planning technique is based on recommendations from the Advisory Committee on Radiation Oncology Practice (ACROP) guideline and the ICRU report 91: Prescribing, Recording and Reporting of Stereotactic Treatments with Small Photon Beams as implemented in the recommendations from the Radiotherapy Committee of Danish Oncology Lung Cancer Group. Planning should be guided by respiratory guided CT scans
Patients who are randomized to have surgery undergo a SWR via a minimal approach (VATS or RATS) during general anesthesia. Pre- and postoperative care and treatment is offered in accordance with local department guidelines. The surgery must be performed or supervised by a specialist in thoracic surgery. The operation is performed with the patient in lateral recumbent position. The surgeon decides the number of ports (1-4), and local analgesic is applied at the incision sites and/or as a nerve block. Additional pain management is registered and performed according to the local practice at the individual department. At the end of surgery, a chest tube is inserted in pleura through one of the ports, and the tube is connected to suction at levels decided by the treating surgeon. Patients in which minimal surgery is converted to thoracotomy are included in an intention-to-treat analysis.
Disease free survival (DFS)
• DFS of patients treated with either surgery (SWR) or SBRT after 3 years
Time frame: 3 years
Life quality
Quality of life after 1, 3, 6, 12 and 36 months PROs are collected from all patients before initiation of treatment (baseline measurements). As soon as the patient is diagnosed with stage I NSCLC and included in the study, a questionnaire will be distributed electronically to the patient using RedCap. When the patient visits the outpatient clinic to receive information concerning the diagnosis and treatment, the doctor informs the patient about the importance of the questionnaire and (if needed) how to fill it out electronically. European Quality of Life - 5 Dimensions (EQ-5D-5L): assess symptom or quality of life issues on a nummerical scale ranging from 1-5 and on a visual analog well being score ranging from 0-100
Time frame: 1, 3, 6, 12 and 36 months
Life quality
Quality of life after 1, 3, 6, 12 and 36 months PROs are collected from all patients before initiation of treatment (baseline measurements). As soon as the patient is diagnosed with stage I NSCLC and included in the study, a questionnaire will be distributed electronically to the patient using RedCap. When the patient visits the outpatient clinic to receive information concerning the diagnosis and treatment, the doctor informs the patient about the importance of the questionnaire and (if needed) how to fill it out electronically. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13): assess symptom or quality of life issues on a nummerical scale ranging from 1-4
Time frame: 1, 3, 6, 12 and 36 months
Life quality
Quality of life after 1, 3, 6, 12 and 36 months PROs are collected from all patients before initiation of treatment (baseline measurements). As soon as the patient is diagnosed with stage I NSCLC and included in the study, a questionnaire will be distributed electronically to the patient using RedCap. When the patient visits the outpatient clinic to receive information concerning the diagnosis and treatment, the doctor informs the patient about the importance of the questionnaire and (if needed) how to fill it out electronically. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 29 (EORTC QLQ-LC29): assess symptom or quality of life issues on a nummerical scale ranging from 1-4
Time frame: 1, 3, 6, 12 and 36 months
Overall survival
Overall survival after 3 and 5 years.
Time frame: 3 and 5 years
Loco-regional recurrence rate
The 2-, 3- and 5-year loco-regional recurrence rate
Time frame: 2, 3 and 5 years
5-year disease free survival
The 5-year disease free survival
Time frame: 5 years
Re-admissions 1
Re-admissions following treatment, adverse reactions and complications ranked by Clavien-Dindo classification. Grade I-V.
Time frame: 1, 3, 6, 12 and 36 months
Re-admissions 2
Re-admissions following treatment, adverse reactions and complications ranked Comprehensive Complication Index (CCI). Nummerical scale, values form 0 to100
Time frame: 1, 3, 6, 12 and 36 months
Re-admissions 3
Re-admissions following treatment, adverse reactions and complications ranked by Common Toxicity Criteria for Adverse Events (CTCAE) version 5. Grade I-V.
Time frame: 1, 3, 6, 12 and 36 months
Health-care related costs
Health-care related costs within 12 and 36 months following treatment (measured i Euro's)
Time frame: 12 and 36 months
PRO data - other than quality of life 1
PRO data - other than quality of life (health condition, symptoms and functional level). European Quality of Life - 5 Dimensions (EQ-5D-5L): assess symptom or quality of life issues on a nummerical scale ranging from 1-5 and on a visual analog well being score ranging from 0-100
Time frame: 1, 3, 6, 12 and 36 months
PRO data - other than quality of life 2
PRO data - other than quality of life (health condition, symptoms and functional level). The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13): assess symptom or quality of life issues on a nummerical scale ranging from 1-4
Time frame: 1, 3, 6, 12 and 36 months
PRO data - other than quality of life 3
PRO data - other than quality of life (health condition, symptoms and functional level). The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 29 (EORTC QLQ-LC29): assess symptom or quality of life issues on a nummerical scale ranging from 1-4
Time frame: 1, 3, 6, 12 and 36 months
Lung function test
Lung function test after 12 month (FEV1 in %, scale: 0-100)
Time frame: 12 months
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: 1 September 2026
Access criteria: By contacting the principal investigator
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Aug 2030, 47 months after the start.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 47 months is above that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.